Prof Karine Clément, MD, PhD, is full professor at Paris 6 Pierre et Marie Curie university of Nutrition and director of the Center of Excellence ICAN Institute de CardiometAbolism and Nutrition, at La Pitié-Salpetrière Hospital, dedicated to innovative Care, Research and training in the field of Cardiology and metabolic diseases. Clément’s work led to the identification of monogenic forms of obesity (Leptin receptor and MC4R mutations) and to several genetic risk factors in common obesity. She contributed to more than 200 international publications, reviews and many international conferences in the field. She performed a post-doctoral fellowship at Stanford University, CA, USA where she acquired competencies in gene profiling approaches applied to complex diseases (1999-2000). In 2001 she obtained a young INSERM “Avenir” team focused on the characterization of patterns of gene expression induced by environmental perturbations. Since January 2006, she is director of the INSERM team Nutrition and obesity (Nutri0mique) and joined in 2007 the Cordelier Research Center. She is a member and expert of several national and international scientific committees in obesity and metabolism and contributes to several European Networks in genetics and functional genomics (Diogenes, Hepadip, ADAPT, FLIP and recently METACARDIS). Metacardis explores the role of gut microbiota in cardiometabolic diseases.
Dr. David E. Cummings, M.D. is a Professor of Medicine (Endocrinology) at the University of Washington, based at the Diabetes and Obesity Center of Excellence and the Seattle VA Hospital. He studies hormonal pathways regulating appetite, body weight, and glucose homeostasis. A major focus is to elucidate hormonal mechanisms mediating the effects of bariatric/metabolic surgery on diabetes and body weight, as well as to determine the role of surgery in diabetes care using randomized trials. Dr. Cummings is a summa cum laude graduate of Dartmouth College, where he majored in Biochemistry. He obtained his medical degree from Harvard Medical School and the Massachusetts Institute of Technology. He is a recipient of the Presidential Early Career Award for Scientists and Engineers – the highest award conferred by the U.S. government to researchers in their early independent careers. It was given by President George W. Bush and included seven years of research funding. He also received the Ethan Simms Young Investigator Award from The Obesity Society, the Philip J. Fialkow Scholar Award from the University of Washington, the Outstanding Investigator Award from the Western Society for Clinical Investigation, and the Endocrine Society’s 2009 Pfizer International Award.
Juergen Eckel studied chemistry and biochemistry at the Universities of Duesseldorf and Bonn, Germany, and graduated with a PhD in 1977 on a topic related to thyroid hormone physiology. He then started to work at the German Diabetes Center in Düsseldorf, Germany, and performed studies on insulin action and insulin resistance in cardiomyocytes. He received the Basedow Award in 1979 and the Jühling award for outstanding diabetes research in 1985. In 1992 Juergen Eckel became a Professor of Clinical Biochemistry at the University of Düsseldorf. He was head of a research group on insulin signaling from 1989 to 2006 and was Acting Director of the Institute of Clinical Biochemistry and Pathobiochemistry from 2006 until 2011. He was Chairman of the European COST Action BM0602 from 2007 until 2011 and coordinator of the FP7 project ADAPT from 2008 until 2012. He is Editor-in-Chief of APB and Editorial Board member of several Journals. His major interest is insulin resistance, adipokine and adipose tissue biology, organ crosstalk, and integrative physiology of insulin action. Since 2011 he is Head of the Paul-Langerhans-Group at the German Diabetes Center.
Prof. Joerg Heeren, PhD is currently Professor at the Institute for Biochemistry and Molecular Cell Biology at the University Medical Center Hamburg-Eppendorf, Germany. He received his PhD in 1998 on a thesis investigating the cell biology of apolipoprotein E in hepatocytes. His main research interest is to understand molecular mechanisms causing abnormalities in lipid and lipoprotein metabolism, which are associated with the development of chronic inflammatory disorders such as atherosclerosis and type 2 diabetes. More recently, Prof. Heeren has utilized state of the art nanoparticle-based metabolic imaging to unravel the contribution of brown, brite and white adipocytes in systemic energy metabolism.
Min-Seon Kim received her M.D. and Ph.D. from the Seoul National University College of Medicine. She trained research fellowship at Imperial College School of Medicine, UK. She is currently an associate professor in division of endocrinology and metabolism of the Asan Medical Centre in Seoul, Korea and a chair of the scientific committee of the Korean Scociety of Study of Obesity. Her major research interest is to understand molecular mechanisms by which the CNS regulates food intake and energy metabolism and to indentify novel appetite regulators. She published over 80 peer-reviewed papers in highly-ranked international journals including Nature Medicine, Nature Neuroscience, Nature Communications and Diabetes and won many awards from the Korean Academic Societies for her scientific achievement.
Carey Lumeng M.D. Ph.D. is an Assistant Professor in Pediatrics and Physiology at the University of Michigan Medical School. His laboratory is interested in the links between obesity, inflammation, and metabolic dysfunction. Specifically, his lab researches the mechanisms by which activation of adipose tissue macrophages and lymphocytes controls adipose tissue function.
Kazuhisa Maeda graduated from Osaka University Medical School in 1989. In 1996, he discovered Human Adiponectin (apM1) in the Human Genome Project while working as a Research fellow in Institute for Molecular and Cellular Biology in Osaka University. He worked as a Cardiologist in Toyonaka Municipal Hospital from 1997. In 1999, he conducted Nutritional Research against Metabolic Syndrome while working as a Research associate in Harvard School of Public Health, Department of Nutrition. In 2002, he worked as a Chief scientist at Medical Center for Translational Research, Osaka University and conduced Regeneration therapy with Human Fat Tissue. From 2006, he worked as an Assistant Professor at the Department of Metabolic Medicine, Osaka University Hospital. He has been working at a current position since 2009.
Wouter van Marken Lichtenbelt
Wouter van Marken Lichtenbelt is leader of the research group on energy metabolism and thermoregulation at the department of Human Biology (NUTRIM School for Nutrition, Toxicology and Metabolism), Maastricht University, The Netherlands. He obtained his PhD at the University of Groningen on ecological energetics of green iguanas. Over 20 years ago his research switched from animal to human physiology. Main emphasis is on individual differences in whole body physiology, the underlying mechanisms on cellular and molecular level, and on numerical modeling of human thermoregulation. A fundamental aspect of the research line is non-shivering and diet-induced thermogenesis. An important recent development is the study of brown adipose tissue. This part of the research bridges the gap between whole body human metabolic studies and recent developments on the regulation of fat and muscle tissue, the recruitment of brown adipose tissue, and mitochondrial function in relation to the metabolic syndrome. Much attention is given on how environmental conditions relate to thermal comfort, long-term health and prevention of obesitas. The results of the different studies are used for the development of a numerical thermo-physiological model.
Dr. Randy Seeley is Professor of Medicine and holds the Donald C. Harrison Endowed Chair at the University of Cincinnati College of Medicine. In 2009, Dr. Seeley was appointed as the Director of the Cincinnati Diabetes and Obesity Center (CDOC). Dr. Seeley received his B.A. from Grinnell College in 1989 and his Ph.D. from the University of Pennsylvania in 1993. He has published over 245 peer-reviewed articles including articles and collectively, this work has been cited more than 20,000 times. He is the recipient of the 2003 Lilly Scientific Achievement Award from the North American Association for the Study of Obesity (now named The Obesity Society) given to the individual with the highest level of scientific achievement in obesity research in North America less than 15 years after their terminal degree. He is also the co-recipient of the 2008 Ernst Oppenheimer award from the Endocrine Society. He also received the 2009 Outstanding Scientific Achievement Award from the American Diabetes Association. Dr. Seeley has also served on numerous review panels for the NIH and was Chair of the Integrative Physiology of Obesity and Diabetes review panel. He currently serves on the NIDDK Clinical Obesity Research Panel and on the Board of Reviewing Editors for Science.
Dr. Sugii graduated from Kyoto University, Japan. He received his Ph.D. in Molecular and Cellular Biology at Dartmouth Medical School (U.S.A.), where he studied intracellular cholesterol homeostasis and transport. He then moved to the Salk Institute for Biological Studies and Howard Hughes Medical Institute (La Jolla, California) to conduct his postdoctoral research on roles of nuclear receptors in adipocyte biology and metabolism with Professor Ronald Evans. He was a recipient of Kakiuchi Yoshinobu Memorial Award from Japanese Society for Science and Technology Studies in 2009. Since January 2011, he has assumed a joint appointment as Group Leader of Fat Metabolism and Stem Cell Group at Singapore Bioimaging Consortium, A*STAR and as Assistant Professor of Cardiovascular and Metabolic Disorders Program at Duke-NUS Graduate Medical School. His current research interests include the characterization and clinical application of adipose-derived stem cells.
Matthias H. Tschöp received his M.D. from Ludwig-Maximilians University in Munich in 1994. After a residency in internal medicine and a fellowship in neuroendocrinology, Dr. Tschöp joined the Eli Lilly Research Laboratories where he discovered the orexigenic, adipogenic, and metabolic effects of ghrelin as well as its regulation by nutrients and body weight, establishing one of today's fundamental pathways. He went on to join the University of Cincinnati, where he was the Arthur Russell Morgan Endowed Chair of Medicine. Together with his long-term collaborator Richard DiMarchi he established a series of novel gut hormone-based single molecule combinatorial therapeutics, several of which are now in clinical development for the treatment of diabetes and obesity. He currently serves as the Research Director of the Helmholtz Diabetes Center, Alexander-von-Humboldt Professor and Chair of Metabolic Diseases at Helmholtz Zentrum and Technische Universität München.
Yu-Hua Tseng received her doctorate in Developmental Biology and Cellular and Molecular Biology from the University of Wisconsin-Madison under the supervision of Dr. Linda Schuler. She completed postdoctoral training in the laboratory of Dr. C. Ronald Kahn at Joslin Diabetes Center/Harvard Medical School. She is an Investigator in the Section on Integrative Physiology and Metabolism at Joslin Diabetes Center, an Assistant Professor of Medicine at Harvard Medical School, and a Principal Faculty of Harvard Stem Cell Institute. Tseng’s current research focuses include brown fat development and function, and regulation of systemic energy metabolism. Dr. Tseng was an Eleanor and Miles Shore Scholar in Medicine at Harvard Medical School.
Dr. Aimin Xu is currently a professor at Department of Medicine and Department of Pharmacology and Pharmacy, also the director of state key laboratory of pharmaceutical biotechnology at the University of Hong Kong. His major research interest is on discovery and functional characterization of novel adipokines and hepatokines involved in the pathogenesis of obesity-related cardio-metabolic complications. His team reported the hepatoprotective and vasculoprotective effects of adiponectin, and also discovered the circulating form of adipocyte fatty acid binding protein (A-FABP) and lipocalin-2 as pro-inflammatory adipokines in both rodents and humans. In addition, his work contributed significantly to the understanding of the molecular basis of adipose tissue inflammation, cross-talk between adipose tissue and blood vessels in the pathogenesis of vascular dysfunctions in obesity and diabetes. His team has developed a series of immunoassay products that have now been widely used for clinical diagnostics, drug screening, clinical and basic research related to obesity and its associated medical complications.
Jianping Ye received his M.D. degree from the Beijing Medical University, China, working on immunology, followed by post-doctoral training in cancer immunology at the National Cancer Institute/NIH and Johns Hopkins University during 1992-1996 in USA. Jianping is interested in cellular and molecular mechanisms of obesity-associated inflammation regarding insulin resistance. He has approached the question with a mouse model of inflammation, bariatric surgery, and dietary supplementation. Observations from his laboratory suggest that: (1) Obesity-associated chronic inflammation is derived from a hypoxia response in adipose tissue; (2) The inflammation stimulates whole body energy expenditure and promotes angiogenesis in adipose tissue. (3) Dietary fiber stimulates energy expenditure through short chain fatty acids (butyric acid), which regulates gene expression through epigenetic mechanism; (4) Herbal extract berberine regulates energy metabolism by inhibiting mitochondrial function, which leads to activation of AMPK; (5) Establishment of Roux-en Y gastric bypass (RYGB) mouse model that resembles the surgery effect in human.